Biovance Capital joins the reputable EU Life Sciences ESG Knowledge Project, leveraging its expertise in sustainable biotech investing to enhance industry-wide ESG standards.
Lisbon, Portugal – 30 June 2025 – Biovance Capital is delighted to announce that it has joined the EU Life Sciences ESG Knowledge Project, a pioneering initiative coordinated by Grant Thornton’s Impact House with the collaboration of 25 leading Life Science venture capital (VC) firms across Europe. This strategic partnership aims to harmonize ESG approaches within the European Life Science investment community, creating a unified framework for sustainability measurement and reporting.
The EU Life Sciences ESG Knowledge Project represents a significant step toward industry standardization, enabling venture capital firms like Biovance Capital to employ consistent methodologies for ESG data collection and analysis. Biovance Capital is particularly enthusiastic about contributing to this collaborative effort, which aligns perfectly with its commitment to promoting environmental, social, and governance excellence within its investment portfolio.
“We look forward to actively participating in this growing community of European Life Science VC firms, sharing insights, and contributing to the evolution of ESG best practices within the biotechnology investment landscape”, said Ricardo Perdigão Henriques, PhD, Managing Partner at Biovance Capital. “By joining the EU Life Sciences ESG Knowledge Project alongside leading European VCs such as Forbion, EQT, Gilde Healthcare, and others, Biovance Capital is reinforcing its dedication to responsible investment practices in the biotechnology sector”, said João Incio, General Partner at Biovance. André Albergaria, Principal at Biovance, added: “This collaboration allows us to leverage collective industry expertise while ensuring our portfolio companies meet the highest sustainability standards in a consistent and measurable way.”
About Biovance Capital
Biovance Capital is Portugal’s leading life sciences venture capital firm. The company manages Biovance Capital Fund I, a new venture capital fund with a total of € 57 million from the European Investment Fund, the national promotional bank Banco Português de Fomento, the European Commission through the Portugal Tech and InvestEU programmes, and private investors from Portugal and abroad. The fund invests in early-stage drug development companies across Europe, with a special focus on Southern Europe.
About EU Life Sciences ESG Knowledge Project
The EU Life Sciences ESG Knowledge Project, with participation from 23 Life Science General Partners, aims to coordinate approaches on ESG within the European Life Science investment community, supported by Impact House by Grant Thornton.
More information: https://www.grantthornton.nl/en/insights-en/advisory/the-eu-life-sciences-esg-knowledge-project/